T1	intervention 0 11	Anastrozole
T2	control 19 28	tamoxifen
T5	outcome-Measure 1290 1304	all recurrence
T7	total-participants 1746 1750	2980
T8	intervention-participants 1856 1860	1449
T9	control-participants 1885 1889	1489
T10	outcome 1955 1980	breast cancer recurrences
T11	outcome 2048 2066	overall recurrence
T12	iv-bin-abs 2068 2070	67
T13	cv-bin-abs 2102 2104	77
T14	outcome 2287 2293	deaths
T15	iv-bin-abs 2309 2311	33
T16	cv-bin-abs 2331 2333	36
T17	outcome 2487 2500	adverse event
T18	iv-bin-abs 2534 2538	1323
T19	iv-bin-percent 2546 2549	91%
T20	cv-bin-abs 2566 2570	1379
T21	cv-bin-percent 2578 2581	93%
T22	outcome 2646 2655	fractures
T23	outcome 2657 2679	musculoskeletal events
T24	outcome 2681 2702	hypercholesterolaemia
T25	outcome 2708 2715	strokes
T26	outcome 2742 2754	muscle spasm
T27	outcome 2756 2791	gynaecological cancers and symptoms
T28	outcome 2793 2811	vasomotor symptoms
T29	outcome 2817 2837	deep vein thromboses
T3	eligibility 767 848	women who had been diagnosed with locally excised, hormone-receptor-positive DCIS
T4	outcome 2863 2871	efficacy
